Genmab — December 2022
-
Godmorgen
-
#ASH22 Talquetamab, a GPRC5D x CD3 Bispecific Antibody, in Patients with RRMM. At 0.4 mg/kg/week: ORR 73%, median PFS 7.5 months. https://twitter.com/transplant_doc/status/1600722580859949056?s=61&t=xzQrHseV4vIwvZlzzdG0vA
-
Genmab rider på en bølge af succes
David Mygind
Fredag 09. december https://ugebrev.dk/life-science/genmab-rider-paa-en-boelge-af-succes/ -
"Genmab: Præsenterede torsdag data for Gen1042 der var bedre end forventet" https://www.jyskebank.dk/finansnyt/morgennyt/2f4f3c0d-af87-4ffd-94d0-47e163666bb1 -I still can't find anything about it; we'll probably have to wait for the R&D day
-
-
Well, the sky has been quite blue the last 10 years. Why would you make it grey then?
-
You are probably right, we have to go back 10 years to make it look great.I can´t do 10 years, but this 5 years compared to Novo, which steadily pays annual dividend.https://imgur.com/a/DSOpp2a
-
5 years looks okay for. Can I get the same return the next 5 years, I’ll be happy
-
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma https://www.prnewswire.com/news-releases/janssen-submits-biologics-license-application-to-us-fda-for-talquetamab-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-301699241.html
BulderHello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind